ECC No: AAACC 8171DXM001. D. L. No.: 1/RR/AP/98/F/R.

E-mail: concorddrugsltd@rediffmail.com concorddrugsltd@gmail.com



CONCORD DRUGS LIMITED

(A PHARMACEUTICAL FORMULATIONS UNIT)

CORPORATE OFFICE: # 3-11-1/1, L.B. Nagar, Hyderabad - 500 074. A.P. India.

Tel: 091-40-24037763, 24036379

Earnings Per Share(of Rs.10/- each) (not annualised)

a) Basic

b) diluted

	Statement of Unaudited Results for the Quarter Ended 30/09/2013	Three	Three	Three	Haif Year Ended	Half Year Ended	Year Ended
	TI Management	months	months	months	30.09.2013	30.09.2012	31.03.2013
390	Particulars	30.09.2013	30.06,2013	30.09.2012	(Un-Audited)	(Un-Audited)	(Audited)
No.		un- Audited)	(Un-Audited)	(Un-Audited)	(UII-Addited)		
					4 676 49	1,391.48	2,806.73
1	Income from Operations :	815.30	760.13	701.25	1,575.43	1,001.40	3 * 2
1	(a) Net Sales / Income from Operations (Net of Excise Duty)	2.89	1.30		4.19	1,391.46	2,806.73
	(b)Other Oprating Income	818.19	761.43	701.25	1,579.63	1,381,40	
	Total Income From operations (net)	270.122		tan man	1000000000	07.24	56.74
		29.21	21.25	13.99	50.46	27.21	2,345,64
2	Expenses:	The state of the s	825.07	582.28	1,287.43	1,161.47	2,040,04
	a) Operating Expenses b) Purchases of stock in trade	662.36	020.0	1			0.21
	b) Purchases of stock in trade c) Changes in inventories of finished goods Work-in-progress and	(2.12)	(1.20)	0.10	(3.32)	(0.40)	32.47
	c) Changes in inventorios of the	(2.12)	9.24		21.49	15.09	71.70
	stock-in-goods	12.25	25.25		51.53	34.70	44.10
	d) Employee benefits expense e) Depreciation and amortisation expense	26.28		100000000000000000000000000000000000000	25.62	21.51	100000
	e) Depreciation and amortisation see	13.26			7.20	7.50	15.15
	f) Power And Fuel	3.96	74.00		41.61	38.13	80.98
	g) Freight and Forwarding Expenses	20,36		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1,482.01	1,305.21	2,646.99
	h) Other Expenses	765.56	716.48	000,00	259	1000	MARRIA
	Total Expenses (a+b+c+d+e+f+g+h) Profit/(Loss) from operations before other income and Finance			45.38	97.61	86,25	159.74
	Profit/(Loss) from operations perore other income	52.64	44.98		The state of	× ×	
3	costs (1-2)				97.61	86.25	159.7
4	Other Income	52.84	44.9	The second	77.88		51.6
5	Other Income Profit/(Loss) From ordinary activities before finance Cost (3+/(-)4)	42.2	35.6		19.73		108.1
6		10.3	9.3	5 33.11	38.44		
7	Profit/(Loss) from ordinary activities before Tax (5+/(-)6)		¥	-	190	1.0	(35.3
В	Tax expenses	1	.(1)		1.00	20.00	39.3
U	(a) Current Tax	2.0	0 2.0	0 10.00	(2)		The second secon
	(b) Deferred Tax	2.0	The second secon		(I)	7 / Care	
	Total (ash)	8.3	A STATE OF THE PARTY OF THE PAR	23.11	15.7	•	1000
9	Net profit/(loss) for the period (7+/(-)8)					1/1/200	104.
	The same of the sa	8.3	7.5	35 23.11		7/2021/220	100000
10	Toyes and minority littless (V.)	2.5		27.5	724.3	8 724.38	124.
11	The state of the s	724.3	7240	.113.000	218-101	11	500
12	Paid up Equity Share Capital (Pace Value of No. 10) Reserves excluding Revaluation Reserve as per balance sheet at ye	ar	13.	3. 3.83	8	*	503.8
13	The state of the s				1 023	0.5	8 13
1 19	end (not annualised)	7.00	4	10 0.3	2 0.2	0.0	200



0.22

0.32

0.32

0.10

0.10

0.12

0.12

0.58

1.44

Part II

	Select Information for the Quarter and year Ended 30/09/2013	Standalone						
20 (20)		Three months	Three months	Three months	Half Year Ended	Half Year Ended	Year Ended	
SI. No.	Particulars	30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	31.03.2013	
		AND DESCRIPTION OF THE PERSON NAMED IN	(un audited)	(un audited)	(un audited)	(Un-Audited)	(Audited)	
1	Public Shareholding	1000	2000000	(www.com)	N/KNAC4N	MXXXIACO.	0.04455.63	
	- Number of shares (000's)	4403250	4403250	4403250	4403250	4403250	4403250	
	- Percentage of Shareholding	60.79%	60.79%	60.79%	60.79%	60.79%	60,799	
2	Promoter and Promoter group Shareholding(ExcludingGDRS)							
	a) Pledged/Encumbered					9		
	- Number of Shares (000's)		-		120		**	
	- Percentage of shares (As a % of total shareholding of Promoer							
	and promoter group	**	#5		1,77		**	
	- Percentage of shares (As a % of total share Capital of the							
	Company) (**	**	
	b) Non-Encumbered				20,404.00	2040500	204050	
	- Number of Shares (000's)	2840500	2840500	2840500	2840500	2840500	284050	
	- Percentage of shares (As a % of total shareholding of Promoer	SECURITION	STANCAGEN		400 0000	100.00%	100,009	
	and promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.009	
	- Percentage of shares (As a % of total share Capital of the	2000	20.244	20.040	39,21%	39.21%	39.219	
	Company	39.21%	39.21%	39,21%	39,2176	38.2176	.39.217	
	Particulars	The Months ended 30/09/2013						
1	INVESTOR COMPLAINTS	and and a second						
	Pending at the beginning of the quarter	NIL NIL						
	Received during the quarter	NIL NIL						
	Disposed of during the quarter	NIL	AND THE PROPERTY OF THE PROPER					
	Remaining unresolved at the end of the quarter	NIL	NIL					

- 1 The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.10.2013
- 2 The Accounting Standard 17 relating to Segment wise reporting is not applicable as the company operates in only one segment viz, Pharmaceuticals
- 3 There were no complaints from investors outstanding at the beginning of the Quarter ended 30th Sep 2013 and the Company has not received any complaints during the quarter ended 30th Sep 2013
- 4 Previous period / year figures have been regrouped wherever necessary.

Station: HYDERABAD Date: 14.10.2013

For Concord Drugs Limited

S. Nagl Reddy Managing director